يعرض 1 - 20 نتائج من 402 نتيجة بحث عن '"Dmitrieva, I"', وقت الاستعلام: 0.59s تنقيح النتائج
  1. 1
    Report
  2. 2
    Academic Journal

    المؤلفون: Dmitrieva, I. G.1 (AUTHOR) irina.bona.mente@gmail.com, Vasilin, V. K.2 (AUTHOR), Dotsenko, V. V.3,4 (AUTHOR) victor_dotsenko_@mail.ru, Aksenov, N. A.4 (AUTHOR)

    المصدر: Russian Journal of General Chemistry. Oct2024, Vol. 94 Issue 10, p2603-2615. 13p.

  3. 3
    Academic Journal
  4. 4
    Academic Journal
  5. 5
  6. 6
  7. 7
    Academic Journal
  8. 8
    Academic Journal
  9. 9
    Academic Journal
  10. 10
    Academic Journal
  11. 11
    Academic Journal
  12. 12
    Academic Journal
  13. 13
    Academic Journal
  14. 14
    Academic Journal
  15. 15
    Academic Journal
  16. 16
    Conference

    المؤلفون: Dmitrieva, I., Blanc, W., Petit, L.

    المساهمون: Tampere University, Physics

    مصطلحات موضوعية: 114 Physical sciences

    وصف الملف: fulltext

    Relation: 2020 22nd International Conference on Transparent Optical Networks, ICTON 2020; 2020-July; https://trepo.tuni.fi/handle/10024/130027

  17. 17
    Academic Journal
  18. 18
    Academic Journal

    المساهمون: Исследование выполнено при финансовой поддержке Совета по грантам Президента Российской Федерации для государственной поддержки молодых российских ученых (МД- 2788.2019.7).

    المصدر: Bulletin of Siberian Medicine; Том 19, № 3 (2020); 76-82 ; Бюллетень сибирской медицины; Том 19, № 3 (2020); 76-82 ; 1819-3684 ; 1682-0363 ; 10.20538/1682-0363-2020-19-3

    وصف الملف: application/pdf

    Relation: https://bulletin.tomsk.ru/jour/article/view/2984/1793; https://bulletin.tomsk.ru/jour/article/view/2984/2230; Vesely M.D., Kershaw M.H., Schreiber R.D., Smyth M.J. Natural innate and adaptive immunity to cancer. Ann. Rev. Immunol. 2011; 29: 235–271. DOI:10.1146/annurev-immunol- 031210-101324.; Tosolini M., Kirilovsky A., Mlecnik B., Fredriksen T., Mauger S., Bindea G., Berger A., Bruneval P., Fridman W.H., Pagès F., Galon J. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, TH2, Treg, TH17) in patients with colorectal cancer. Cancer Res. 2011; 71 (4): 1263–1271. DOI:10.1158/0008-5472.CAN-10-2907.; Noguchi A., Kaneko T., Naitoh K., Masashi S., Iwai K., Maekawa R., Kamigaki T., Goto S. Impaired and imbalanced cellular immunological status assessed in advanced cancer patients and restoration of the T cell immune status by adoptive T-cell immunotherapy. International Immunopharmacology. 2014; 18 (1): 90–97. DOI:10.1016/j.intimp.2013.11.009.; Smyth M.J., Dunn G.P., Schreiber R.D. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv. Immunol. 2006; 90: 1–50. DOI:10.1016/S0065-2776(06)90001-7.; Chang W., Tsai M., Kuo P., Hung J. Role of galectins in lung cancer. Oncol. Lett. 2017; 14 (5): 5077–5084. DOI:10.3892/ol.2017.6882.; Orozco C.A., Martinez-Bosch N., Guerrero P.E., Vinaixa J., Dalotto-Moreno T., Iglesias M., Moreno M., Djurec M., Poirier F., Gabius H.J., Fernandez-Zapico M.E., Hwang R.F., Guerra C., Rabinovich G.A., Navarro P. Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor-stroma crosstalk. Proc. Nat. Acad. Sci. USA. 2018: 115 (16): 3769–3778. DOI:10.1073/pnas.1722434115.; Chou F., Chen H., Kuo C., Sytwu H. Role of galectins in tumors and in clinical immunotherapy. Int. J. Mol. Sci. 2018; 19 (2): 430. DOI:10.3390/ijms19020430.; Колобовникова Ю.В., Дмитриева А.И., Янкович К.И., Васильева О.А., Пурлик И.Л., Новицкий В.В., Уразова О.И., Хардикова С.А. Галектин-1-опосредованная экспрессия белков-регуляторов клеточного цикла и ростовых факторов при раке желудка. Бюллетень сибирской медицины. 2017; 16 (4): 165–172. DOI:10.20538/1682-0363-2017-4-165-172.; Cedeno-Laurent F., Opperman M., Barthel S.R., Kuchroo V.K., Dimitroff C.J. Galectin-1 triggers an immunoregulatory signature in Th cells functionally defined by IL-10 expression. J. Immunol. 2012; 188 (7): 3127–3137. DOI:10.4049/jimmunol.1103433.; Cedeno-Laurent F., Watanabe R., Teague J.E., Kupper T.S., Clark R.A., Dimitroff C.J. Galectin-1 inhibits the viability; proliferation, and Th1 cytokine production of nonmalignant T cells in patients with leukemic cutaneous T-cell lymphoma. Blood. 2012; 119 (15): 3534–3538. DOI:10.1182/blood-2011-12-396457.; Fermin L.A., Chen H.Y., Wan L., Wu S.Y., Yu J.S., Huang A.C., Miaw S.C., Hsu D.K., Wu-Hsieh B.A., Liu F.T. Galectin-3 modulates Th17 responses by regulating dendritic cell cytokines. Am. J. Pathol. 2013; 183 (4): 1209–1222. DOI:10.1016/j.ajpath.2013.06.017.; Radosavljevic G., Jovanovic I., Majstorovic I., Mitrovic M., Lisnic V.J., Arsenijevic N., Jonjic S., Lukic M.L. Deletion of galectin-3 in the host attenuates metastasis of murine melanoma by modulating tumor adhesion and NK cell activity. Clin. Exp. Metastasis. 2011; 28 (5): 451–462. DOI:10.1007/s10585-011-9383-y.; Kovács-Sólyom F., Blaskó A., Fajka-Boja R., Katona R.L., Végh L., Novák J., Szebeni G.J., Krenács L., Uher F., Tubak V., Kiss R., Monostori E. Mechanism of tumor cell-induced T-cell apoptosis mediated by galectin-1. Immunol. Lett. 2010; 127 (2): 108–118. DOI:10.1016/j.imlet.2009.10.003.; Rabinovich G.A., Conejo-García J.R. Shaping the immune landscape in cancer by galectin-driven regulatory pathways. J. Mol. Biol. 2016; 428 (16): 3266–3281. DOI:10.1016/j.jmb.2016.03.021.; Van den Brûle F., Califice S., Castronovo V. Expression of galectins in cancer: a critical review. Glycoconj. J. 2002; 19 (7-9): 537–542. DOI:10.1023/B:GLYC.0000014083.48508.6a.; Thijssen V.L., Heusschen R., Caers J., Griffioen A.W. Galectin expression in cancer diagnosis and prognosis: A systematic review. Biochim. Biophys. Acta. 2015; 1855 (2): 235–247. DOI:10.1016/j.bbcan.2015.03.003.; Колобовникова Ю.В., Дмитриева А.И., Янкович К.И., Васильева О.А., Пурлик И.Л., Полетика В.С., Новицкий В.В., Уразова О.И. Экспрессия галектинов-1, 3 при раке желудка и толстой кишки с тканевой эозинофилией. Бюллетень экспериментальной биологии и медицины. 2018; 165 (2): 220–223.; Wu K.L., Chen H.H., Pen C.T., Yeh W.L., Huang E.Y., Hsiao C.C., Yang K.D. Circulating galectin-1 and 90k/mac-2bp correlated with the tumor stages of patients with colorectal cancer. Biomed. Res. Int. 2015; 2015: 306964. DOI:10.1155/2015/306964.; Hittelet A., Legendre H., Nagy N., Bronckart Y., Pector J.C., Salmon I., Yeaton P., Gabius H.J., Kiss R., Camby I. Upregulation of galectins-1 and -3 in human colon cancer and their role in regulating cell migration. Int. J. Cancer. 2003; 103 (3): 370–379. DOI:10.1002/ijc.10843.; Endo K., Kohnoe S., Tsujita E., Watanabe A., Nakashima H., Baba H., Maehara Y. Galectin-3 expression is a potent prognostic marker in colorectal cancer. Anticancer Res. 2005; 25 (4): 3117–3121.; Okada K., Shimura T., Suehiro T., Mochiki E., Kuwano H. Reduced galectin-3 expression is an indicator of unfavorable prognosis in gastric cancer. Anticancer Res. 2006; 26 (2B): 1369–1376.; Tsuboi K., Shimura T., Masuda N., Ide M., Tsutsumi S., Yamaguchi S., Asao T., Kuwano H. Galectin-3 expression in colorectal cancer: relation to invasion and metastasis. Anticancer Res. 2007; 27 (4B): 2289–2296.; Kennedy R., Celis E. Multiple roles for CD4+ T cells in anti‐tumor immune responses. Immunological Reviews. 2008; 222 (1): 129–144. DOI:10.1111/j.1600-065X.2008.00616.x.; Ling A., Lundberg I.V., Eklöf V., Wikberg M.L., Öberg Å., Edin S, Palmqvist R. The infiltration, and prognostic importance, of Th1 lymphocytes vary in molecular subgroups of colorectal cancer. J. Pathol. Clin. Res. 2016; 2 (1): 21–31.; De Simone V., Pallone F., Monteleone G., Stolfi C. Role of TH17 cytokines in the control of colorectal cancer. Oncoimmunology. 2013; 2 (12): e26617. DOI:10.4161/onci.26617.; Amicarella F., Muraro M.G., Hirt C., Cremonesi E., Padovan E., Mele V., Governa V., Han J., Huber X., Droeser R.A., Zuber M., Adamina M., Bolli M., Rosso R., Lugli A., Zlobec I., Terracciano L., Tornillo L., Zajac P., Eppenberger-Castori S., Trapani F., Oertli D., Iezzi G. Dual role of tumour-infiltrating T helper 17 cells in human colorectal cancer. Gut. 2017; 66 (4): 692–704. DOI:10.1136/gutjnl-2015-310016.; Bonertz A., Weitz J., Pietsch D.H., Rahbari N.N., Schlude C., Ge Y., Juenger S., Vlodavsky I., Khazaie K., Jaeger D., Reissfelder C., Antolovic D., Aigner M., Koch M., Beckhove P. Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J. Clin. Invest. 2009; 119 (11): 3311–3321. DOI:10.1172/JCI39608.; Васильева О.А., Прохоренко Т.С., Зима А.П., Новицкий В.В. Влияние галектинов на дифференцировку и функциональную активность Th-лимфоцитов in vitro. Медицинская иммунология. 2015; 17 (5): 14.; Toscano M.A., Bianco G.A., Ilarregui J.M., Croci D.O., Correale J., Hernandez J.D., Zwirner N.W., Poirier F., Riley E.M., Baum L.G., Rabinovich G.A. Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death. Nat. Immunol. 2007; 8 (8): 825–834. DOI:10.1038/ni1482.; Васильева О.А., Якушина В.Д., Рязанцева Н.В., Новицкий В.В., Таширева Л.А., Старикова Е.Г., Зима А.П., Прохоренко Т.С., Краснова Ю.В., Небесная И.С. Регуляция экспрессии генов транскрипционных факторов дифференцировки T-лимфоцитов CD4+ галектином-3 in vitro. Молекулярная биология. 2013; 47 (6): 1004–1010. DOI:10.7868/S0026898413060165.; MacKinnon A.C., Gibbons M.A., Farnworth S.L., Leffler H., Nilsson U.J., Delaine T., Simpson A.J., Forbes S.J., Hirani N., Gauldie J., Sethi T. Regulation of Transforming Growth Factor-β1–driven Lung Fibrosis by Galectin-3. Am. J. Respir. Crit. Care Med. 2012; 185 (5): 537–546. DOI:10.1164/rccm.201106-0965OC.; https://bulletin.tomsk.ru/jour/article/view/2984

  19. 19
    Academic Journal
  20. 20
    Academic Journal